Search
Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)
CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.
Read moreEU commissioner Tonio Borg: 'we will continue to improve the life of people suffering from Thalassaemia'
Today, May 8, is International Thalassemia Day. Today, we seek to enhance the awareness and knowledge of thalassemia and other hemoglobin disorders.
Invitation: “Can EU citizens afford their medicines? The economic crisis and access to medicines in Europe“
For more information, please find the full invitation here
Read moreMay 8 - International Thalassaemia Day
Every year on the 8th May, Thalassaemia International Federation commemorates the International Thalassaemia Day and organises activities for raising awareness about the genetic blood disorder of thalassaemia, on general topics regarding its prevention, management and cure.
Read moreWide Consensus Reached at Irish Presidency Conference on ‘Innovation and Patient Access to Personalised Medicine'
DUBLIN, March 25: Wide consensus emerged at the Irish Presidency Conference on ‘Innovation and Patient Access to Personalised Medicine’ on the need for radical change if Europe's approach to healthcare is to benefit from the potential of personalised medicine.
Read moreMajor Conference: innovation and patient access to personalised medicine
The meeting will bring together researchers, patients, physicians, regulators and politicians, to explore the current barriers and how they can be dismantled.
Read moreReport on first EHA-SWG Scientific Meeting
The meeting was organized with the main support of the EHA in collaboration with the Hematology Unit of G. Gaslini Children’s Hospital and was sponsored by Novartis and Alexion.
Read moreBreakthrough results in European multicenter trial on acute promyelocytic leukemia (APL): no more chemotherapy?
APL is a rare, yet aggressive, subtype of acute myeloid leukemia (AML) characterized by a maturation arrest of white blood cell precursors in the marrow, leading to a shortage of normal white cells and platelets in the blood, which is…
Read morePRESS RELEASE: Cyprus Presidency promotes win-win on health and competitiveness
The report, “Building an Open Innovation ecosystem in Europe for healthcare”, will be launched at a press conference in the European Parliament in Brussels on 29 November, 2012.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- 172
- 173
- »